Merck Serono: Fresh Pipeline Leads Growth but More Jobs Cuts to Come
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
Merck Serono says “fast progress” in its restructure programme helped double its net savings guidance for 2012 though headcount dropped by almost 2,000 with more cuts to come.
A new partnership between a niche cancer drug discovery company and biotech powerhouse Celgene could pave the way for the future of cancer drug discovery and delivery.
WuXi PharmaTech has expanded its partnership with Open Monoclonal Technology (OMT) to use its transgenic rats and mice in China and other Asian countries.